bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 2377: Design, synthesis, and characterization of 4-aminopyrazole quinazolines as potent inhibitors of G protein-coupled receptor kinase GRK6 for the potential treatment of multiple myeloma
Authors: Uehling David , Joseph Babu , Griffin Carly , Subramaniam Ratheesh , Abibi Ayome , Marcellus Richard , Prakesch Michael , Poda Gennadiy , Isaac Methvin , Leung-Hagesteijn Chungyee , Tiedemann Rodger , Al-awar Rima 
Published: August 2018

Abstract
Multiple myeloma (MM) is one of the most common hematological malignancies, but current therapeutic options are limited to high-dose chemotherapy or high-risk stem-cell transplantation. In a kinome-wide RNAi study by Tiedemann and colleagues (2010), the G-protein coupled receptor kinase GRK6 was identified as a critical kinase required for survival of MM cells. This study also suggests that MM cells, but not other cell types, are dependent on GRK6; and that gene silencing by shRNA or siRNA of GRK6, but not other members of the GRK family, results in decreased survival. Through gene silencing techniques, we determined that a functional GRK6 kinase domain is required for survival of MM cells. These findings helped validate that the kinase domain of GRK6 is a promising target for MM, and therefore encouraged us to embark on an effort to identify potent small molecule kinase inhibitors of GRK6. Toward that end, by screening a focused kinase-directed library of small molecule inhibitors, compounds with moderate potency against GRK6 in biochemical assays were identified. Through this exercise, we discovered that two structurally distinct aminopyrazoles AZ-960 and ASC-082 had modest inhibition of GRK6. By combining structural features of these hits and further optimization we identified the quinazoline analogue OICR9945, a potent GRK6 inhibitor with good selectivity against a panel of diverse kinases and anti-proliferative activity against MM cell lines. Herein, we describe the design, synthesis and early pharmacological characterization of OICR9945 along with structure activity relationships (SAR) of this series against GRK6 and other kinases.
Citation Format: David Uehling, Babu Joseph, Carly Griffin, Ratheesh Subramaniam, Ayome Abibi, Richard Marcellus, Michael Prakesch, Gennadiy Poda, Methvin Isaac, Chungyee Leung-Hagesteijn, Rodger Tiedemann, Rima Al-awar. Design, synthesis, and characterization of 4-aminopyrazole quinazolines as potent inhibitors of G protein-coupled receptor kinase GRK6 for the potential treatment of multiple myeloma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2377.
Abstract 238: Interaction analysis between germline susceptibility loci and somatic alterations in lung cancer
Authors: Wang Yuzhuo , Wang Cheng , Zhu Meng , Jin Guangfu , Shen Hongbing 
Published: August 2018

Abstract
Emerging evidence indicates that germline variations may interact with somatic events in carcinogenesis. However, the germline-somatic interaction in lung cancer remains largely unknown. In the present study, we investigated whether lung cancer driver genes (CDGs) were more likely to locate within cancer susceptibility regions. Additional pathway enrichment analysis was performed to identify common pathways underlying CDGs and cancer susceptibility genes (CSGs). Next, we analyzed the associations between lung cancer risk SNPs and somatic alterations, including mutations and copy number alterations, in the level of genes, pathways, and overall burden of alterations. Enrichment analysis showed that lung CDGs are more likely to locate within cancer susceptibility regions (P = 8.40×10-3). Both of lung CSGs and CDGs showed significant enrichment in pathways such as cell cycle and p53 signaling pathway. Gene-based analysis showed that rs36600 (22q12.2) was associated with somatic mutations within ARID1A (OR = 2.45, 95%CI: 1.47-4.08, P = 5.78×10-4). Pathway-based analysis identified rs2395185 and rs3817963 at 6p22.1 were associated with somatic truncation mutations in cell cycle pathway (OR = 1.56, P = 3.61×10-4 for rs2395185; OR = 1.58, P = 4.15×10-4 for rs3817963), and rs3817963 was also associated with somatic truncation mutations in MAPK signaling pathway (OR = 1.54, P = 8.58×10-4). Further analysis associated rs2395185 at 6p22.1 (HLA class II genes) with increased APOBEC3A expression (P = 9.50×10-3) and elevated APOBEC mutagenesis (P = 3.58×10-3). These results provide evidence for the germline-somatic interactions on lung tumorigenesis. This can help to uncover the molecular mechanisms by which risk SNPs influence lung cancer risk.
Citation Format: Yuzhuo Wang, Cheng Wang, Meng Zhu, Guangfu Jin, Hongbing Shen. Interaction analysis between germline susceptibility loci and somatic alterations in lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 238.
Abstract 2414: Interrogating cellular metabolism reveals mTORC2 as a new biomarker to stratify epidermal growth factor receptor-mutant non-small cell lung cancer
Authors: Chiang Chun-Te , Ung Nolan , Demetriou Alexandra N. , Chiu Chi-Li , Choudhury Niha , Arnesano Cosimo , Fraser Scott E. , Agus David B. , Matasci Naim , Ruderman Dan L. , Mumenthaler Shannon M. 
Published: August 2018

Abstract
Most non-small cell lung cancer (NSCLC) patients with epidermal growth factor (EGFR) mutations initially respond to EGFR tyrosine-kinase inhibitors (TKIs), but these inhibitors are only effective for approximately one year, thus limiting the benefits to patients' survival. Stratification of patients with EGFR-mutant NSCLC would help physicians personalize and optimize patient treatment plans. To this end, we hypothesized that factors residing in the tumor microenvironment play a pivotal role in the evolutionary dynamics of therapeutic response to anti-EGFR therapies. We used the Operetta® High Content Imaging System to track cell dynamics over time under different microenvironmental stresses, and we found that the growth of TKI-resistant cells is more sensitive to glucose starvation than TKI-sensitive cells. To further interrogate cellular metabolism in TKI-sensitive and resistant cells, we utilized both seahorse metabolic assays and fluorescence lifetime imaging microscopy to monitor the changes in glycolysis and oxidative phosphorylation of living cells. We found TKI-resistant cells have higher glycolysis and lower oxidative phosphorylation rates compared to TKI-sensitive cells. Such metabolic reprogramming rendered TKI-resistant cells with lower metabolic plasticity to cope with metabolic stress. Using both genetic and pharmacologic approaches, we then demonstrated that mTORC2 activation contributes to the different metabolic phenotypes between TKI-sensitive and resistant cells. Furthermore, gene set enrichment analysis showed that the oxidative phosphorylation gene set is significantly enriched in patients with low mTORC2 activation, and the glycolysis gene set is upregulated in patients with high mTORC2 activation, which is correlated with shorter progression-free and overall survival time in patients. Overall, these data suggest that TKI-resistant cells use and require distinct metabolic programs that can be employed to stratify EGFR-mutant NSCLC patients for treatment with EGFR-TKIs.
Citation Format: Chun-Te Chiang, Nolan Ung, Alexandra N. Demetriou, Chi-Li Chiu, Niha Choudhury, Cosimo Arnesano, Scott E. Fraser, David B. Agus, Naim Matasci, Dan L. Ruderman, Shannon M. Mumenthaler. Interrogating cellular metabolism reveals mTORC2 as a new biomarker to stratify epidermal growth factor receptor-mutant non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2414.
Abstract 2421: SOD1 is required for tumor maintenance in a genetically engineered KRAS/TP53 non-small cell lung cancer mouse model
Authors: Wang Xiaowen , Wong Justin , Remmen Holly Van , Guo Jessie Yanxiang , White Eileen , Zheng X. F. Steven 
Published: August 2018

Abstract
Lung cancer is the second most common cancer and the primary cause of cancer-related mortality globally. Over half a million people are estimated living with lung and bronchus cancer with a 5-year survival rate of 18%. Identifying and studying new drug targets are important for improving lung cancer patient survival. 80% to 85% of lung cancers are Non-small cell lung cancer (NSCLC). Knocking down and small molecule inhibition of Superoxide dismutase 1 (SOD1) has been shown to be cytotoxic to cultured NSCLC cells and mouse tumors, suggesting that SOD1 is important for NSCLC survival, thus presenting a promising therapeutic strategy. SOD1 rapidly converts superoxide anion to hydrogen peroxide. It is a critical component of the cellular antioxidant defense system. In addition, our laboratory has recently demonstrated that SOD1 has a novel function as a transcription factor that regulates oxidative stress response genes. Currently, there are no selective SOD1 inhibitors available to study physiological functions of SOD1. In our study, we show that genetically knockout SOD1 resulted in reduced tumor burden in lung cancer mouse model. Using mouse tumor-derived primary cancer cells, we further show that SOD1 is critical for NSCLC cell proliferation and survival. This study reveals novel functions of SOD1 that are of biological and translational significance, and provide further support for SOD1 as a promising therapeutic target for NSCLC.
Citation Format: Xiaowen Wang, Justin Wong, Holly Van Remmen, Jessie Yanxiang Guo, Eileen White, X. F. Steven Zheng. SOD1 is required for tumor maintenance in a genetically engineered KRAS/TP53 non-small cell lung cancer mouse model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2421.
Abstract 244: Pathway analysis of OncoArray data identifies biological pathways involved in lung cancer development
Authors: Wang Zhihui , Zhang Ruyang , Su Li , Hung Rayjean , Amos Christopher , Christiani David C. 
Published: August 2018

Abstract
Background:Genome-wide association studies (GWAS) have identified susceptible loci associated with lung cancer development. However, these variants only account for a small proportion of lung cancer heritability. With the aim to identify the missing heritability, we propose to conduct pathway analysis to test the joint effects of rare and common variants using the OncoArray data. By grouping SNPs into genes and pathways, we may shed light into the underlying mechanisms for lung cancer development and identify novel candidate genes and pathways.Methods:We applied sequence kernel association test (SKAT) to the OncoArray data of the Transdisciplinary Research of Cancer in lung of the International Lung Cancer Consortium (TRICL-ILCCO) that includes 34,432 individuals (19,028 cases and 15,404 controls) across over twenty lung cancer studies. A total of 403 KEGG and Biocarta pathways containing 5,555 genes and 58,717 SNPs were included in the study. As a score-based variance-component test, SKAT calculated p values for each pathway set by fitting the null model containing only age, gender, smoking, and first three PCAs. Results:KEGG neuroactive ligand receptor interaction (p=1.18×10-4, FDR=0.0285) and KEGG pancreatic cancer pathways (p=1.41×10-4, FDR=0.0285) were significantly associated with lung cancer. Gene-based analyses found that the most significant genes on the KEGG neuroactive ligand receptor interaction pathway to be CHRNA5 (p=2.33×10-8, FDR=0.0003), CHRNA3 (p=2.85×10-7, FDR=0.0019), and CHRNB4 (p=7.49×10-7, FDR=0.0034), while the most significant genes for KEGG pancreatic cancer pathway to be BRCA2 (p=2.23×10-5, FDR=0.0505). Stratified analyses highlighted five pathways (KEGG intestinal immune network for IGA production, KEGG leishmania infection, KEGG bladder cancer, KEGG pancreatic cancer, and KEGG axon guidance) for squamous cell carcinoma and one pathway (Biocarta ACH pathway) for adenocarcinoma with FWER&lt;0.05. Noteworthy, the most significant gene on ACH pathway for adenocarcinoma was TERT gene, whereas the top two significant pathways for squamous carcinoma shared the most significant HLA-DQA1 gene, along with 11 other HLA genes at 6p21.Conclusion:The results suggest that the underlying pathways differ by cancer cell types and further research should be conducted to investigate the effects of immune pathways and HLA genes on squamous cell carcinoma etiology.
Citation Format: Zhihui Wang, Ruyang Zhang, Li Su, Rayjean Hung, Christopher Amos, David C. Christiani. Pathway analysis of OncoArray data identifies biological pathways involved in lung cancer development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 244.
Abstract 2474: Identification of lncRNAs involved in regulation of chromosome instability-associated genes in a prostate cancer model
Authors: Manriquez Rogelio Montiel , Canon Cristian Gabriel Oliverio Arriaga , Soberanis Fernanda Cisneros , César Cortés Carlo , Velazquez Inti Alberto De La Rosa , Montalvo Luis Alonso Herrera 
Published: August 2018

Abstract
In this study we aim to identify new lncRNAs, using RNA-seq data, and study whether those transcripts could be involved in chromosomal instability in prostate cancer and propose new possible RNA-based biomarkers. Using RNA-seq data from two prostate cell lines, neoplastic and non-neoplastic, we have identified a new lncRNA adjacent to CEP55, a gene associated with chromosomal instability. This lncRNA, which we have named lncRNA-CEP55, is 1.6 kb long and it is downregulated in the neoplastic cell line; this is also seen in the adjacent coding gene, CEP55, where the expression decreases in the neoplastic line, suggesting an important role of this transcript in carcinogenesis. This new lncRNA could be regulating CEP55 expression in these cell lines. Changes in expression of CEP55 have been associated to chromosomal instability and cancer development in colon cancer cell lines. Another lncRNA with differential expression in both cell lines has been identified, lncRNA-RFC4. This lncRNA has been reported before; it is an annotated gene in the human genome GRCh38/hg38, but it has not been studied in cancer. This lncRNA is highly expressed in the neoplastic cell line whereas its expression is very low in the non-neoplastic cell line. This lncRNA is 4.3 kb away from RFC4 (Replication Factor C Subunit 4), a protein coding gene related to mismatch repair and DNA double-strand break repair, which has been associated with chromosomal instability. lncRNA-RFC4 could be playing an important role in the cis regulation of RFC4 gene. lncRNA-CEP55 and lncRNA-RFC4 are important targets of study because of their differential expression in prostate cell lines (neoplastic and non-neoplastic). These lncRNAs could be playing an essential role in regulating the expression of the adjacent genes related to chromosomal instability, a enabling characteristic that facilitates the acquisition of the hallmarks of cancer.
Citation Format: Rogelio Montiel Manriquez, Cristian Gabriel Oliverio Arriaga Canon, Fernanda Cisneros Soberanis, Carlo César Cortés, Inti Alberto De La Rosa Velazquez, Luis Alonso Herrera Montalvo. Identification of lncRNAs involved in regulation of chromosome instability-associated genes in a prostate cancer model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2474.
Abstract 2482: RanBP17 retards the epithelial-mesenchymal transition (EMT) and malignant progression of glioblastoma cells by regulating the exportation of beta-catenin from cell nucleus
Authors: Wang Yi , Guo Penyi , Xie Xiaozai , Zhang Sina , Yu Haitao , Wu Lijun , Chen Ziyan , Chen Gang 
Published: August 2018

Abstract
Background: Glioblastoma multiforme (GBM) is the most common and lethal primary human brain tumor and exhibits multiple molecular aberrations. In this study, we attempted to explore the role of a nuclear transport receptor RanBP17 in carcinogenesis and its underlying mechanisms in GBM.
Methods: The relevant information retrieved from the Human Integrated Protein Expression Database (HIPED), TCGA, and Rembrandt was analyzed to evaluate and compare RanBP17 expression in various tissues and cancer types. Next U87 and U251 were used to investigate the effects of RPS15A on epithelial-mesenchymal transition (EMT) and malignant behaviors of glioma cells. Further, RPS15A-associated signaling pathways were screened based on the data from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database and verified by using RT-PCR and Western blot (WB) assays.
Results: RanBP17 was highly expressed in normal brain tissue, and loss or downregulation of RanBP17 was observed in GBM tissue (83/105, 79.05%) and associated with worse survival of patients. Overexpression of RanBP17 suppressed proliferation, migration and invasion of GBM cells in vitro and remarkably inhibited tumor growth in vivo. In addition, RanBP17 silencing promoted EMT of glioma cells via activating the expression of transcriptional factor Snail. Further experiments confirmed that RanBP17 overexpression promoted the export of β-catenin from cell nuclei and retarded wnt/β-catenin signaling. Conversely, knockdown of RanBP17 gene resulted in accumulation of β-catenin in glioblastoma cell nuclei, which, in turn, promoted expression of EMT-related proteins and malignant progression of glioblastoma by combining other transcript genes.
Conclusions: RanBP17 expression is significantly lower in GBM compared to normal brain tissue. Silencing RanBP17 accelerates the EMT process and malignant progression of glioblastoma due to the suppressed export of β-catenin from glioblastoma cell nuclei and the resulting inhibition of wnt/β-catenin signaling. Therefore, loss or downregulation of RanBP17 can be considered a negative prognostic factor for survival of GBM patients.
Citation Format: Yi Wang, Penyi Guo, Xiaozai Xie, Sina Zhang, Haitao Yu, Lijun Wu, Ziyan Chen, Gang Chen. RanBP17 retards the epithelial-mesenchymal transition (EMT) and malignant progression of glioblastoma cells by regulating the exportation of beta-catenin from cell nucleus [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2482.
Abstract 2494: A novel tool for monitoring endogenous progesterone receptor expression by mCherry using CRISPR-Cas9 genome editing technique
Authors: Li Yiyang , Meng Xiangbing , Wen Kuo-kuang , Wu Meng , Dupuy Adam , Leslie Kimberly , Yang Shujie 
Published: August 2018

Abstract
Expression of progesterone receptor (PR) is a favorable prognostic marker for multiple solid tumors. However, PR expression is reduced or lost in malignant tumors which hinders response to progesterone therapy. Thus, monitoring and restoring functional PR expression is of utmost importance to sensitize progesterone therapy in endometrial cancer. We developed a stable cell line expressing the endogenous PR gene tagged a reporter gene (Hygromycin and mCherry) with CRISPR/Cas9-mediated genome editing. This allows efficient monitoring of PR expression in its native epigenetic landscape. The reporter gene expression faithfully reflects and amplifies PR expression following treatment with histone deacetylase inhibitor, romidepsin. This reporter gene transfected cells were successfully used to screen the FDA-approved 1018 library by high throughput screening in searching of potential novel drugs that increase PR expression. This strategy provides an efficient drug screening tool that can be used to screen novel PR inducers in multiple cancer cell lines.
Citation Format: Yiyang Li, Xiangbing Meng, Kuo-kuang Wen, Meng Wu, Adam Dupuy, Kimberly Leslie, Shujie Yang. A novel tool for monitoring endogenous progesterone receptor expression by mCherry using CRISPR-Cas9 genome editing technique [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2494.
Abstract 2503: Rational design of small-molecule immune checkpoints' inhibitors
Authors: Barakat Khaled 
Published: August 2018

Abstract
Blocking the PD-1/PD-L1 and CTLA-4 pathways recently emerged as a ‘game changer' in cancer immunotherapy, leading to the selection of monoclonal-antibodies (MABs) targeting PD-1 as ‘drug of the year' for 2013. Although these antibodies restored exhausted T cells' function to recognize and kill tumor cells, these MABs have numerous disadvantages. These include their very high cost and very severe side effects. Our team has been focused on designing small molecule inhibitors for this pathway. Compared to available MAB therapies, our small molecules may offer a more affordable, more easily administered and better controlled treatment for a variety of cancers. Here, we demonstrate our efforts toward this goal and summarize our data on our promising compounds targeting the PD-1/PD-L1 and CTLA-4 pathways.
Citation Format: Khaled Barakat. Rational design of small-molecule immune checkpoints' inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2503.